Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Apr 12, 2019
Clinical News

Merrimack discontinues last clinical candidate

BioCentury | Jan 10, 2017
Company News

Ipsen acquiring Merrimack's marketed products

BioCentury | Mar 28, 2016
Strategy

Canbridge can-can

Why Aveo's AV-203 is leading Canbridge to venture outside Asia
BioCentury | Jan 4, 2016
Clinical News

Seribantumab: Phase II amended

BioCentury | Sep 10, 2015
Emerging Company Profile

Epitope as prologue

How Hummingbird develops antibodies against epitopes in natural conformation
BioCentury | Mar 23, 2015
Clinical News

MM-121: Phase II started

BioCentury | Jun 23, 2014
Clinical News

MM-121: Additional Phase II data

BioCentury | Jun 23, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones
Items per page:
1 - 10 of 52